A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumours

Official Title

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumours

Summary:

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumours that have spread to other parts of the body or cannot be removed by surgery, including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumour cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumour, and may help make the tumour more sensitive to olaparib.

Trial Description

Primary Outcome:

• Objective response rate, measured by Response Evaluation Criteria in Solid Tumours version 1.1

Secondary Outcome:

• Incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0
• Progression-free survival

PRIMARY OBJECTIVES:
I. To determine the objective response rate (ORR) of cediranib (cediranib maleate) plus olaparib in combination in patients with advanced or metastatic solid tumours of the following tumour types: non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic ductal adenocarcinoma (PDAC), and small cell lung cancer (SCLC). SECONDARY OBJECTIVES:
I. To assess the safety and tolerability of oral administration of cediranib in combination with olaparib in patients with select advanced solid tumours. II. To estimate progression free survival (PFS) in each tumour cohort. TERTIARY OBJECTIVES:
I. To estimate the prevalence of the mutations of deoxyribonucleic acid (DNA) repair genes in tumours using the BROCA panel and to correlate tumour regression with mutations status. (Integrated) II. To evaluate changes in tumour hypoxia on cediranib treatment compared to baseline by [F-18] fluoromisonidazole (FMISO) positron emission tomography/computed tomography (PET/CT) in patients with NSCLC. III. To evaluate levels of angiogenesis/inflammatory markers including VEGF at baseline and on treatment. IV. To evaluate levels of circulating tumour deoxyribonucleic acid (ctDNA) at baseline and on treatment. OUTLINE:

Patients receive cediranib maleate orally (PO) once daily (QD) on day 1. Patients undergoing FMISO scan also receive olaparib PO twice daily (BID) beginning the day after the second FMISO scan and the rest of the patients receive olaparib PO BID beginning day 4 of course 1. Courses repeat every 28 days (35 days for course 1) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 4 weeks and then every 4 weeks thereafter.

View this trial on ClinicalTrials.gov